The role of CXCL10 in the pathogenesis of experimental septic shock

Daniela S. Herzig, Liming Luan, Julia K. Bohannon, Tracy Toliver-Kinsky, Yin Guo, Edward R. Sherwood

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Introduction: The chemokine CXCL10 is produced during infection and inflammation to activate the chemokine receptor CXCR3, an important regulator of lymphocyte trafficking and activation. The goal of this study was to assess the contributions of CXCL10 to the pathogenesis of experimental septic shock in mice.Methods: Septic shock was induced by cecal ligation and puncture (CLP) in mice resuscitated with lactated Ringer's solution and, in some cases, the broad spectrum antibiotic Primaxin. Studies were performed in CXCL10 knockout mice and mice treated with anti-CXCL10 immunoglobulin G (IgG). Endpoints included leukocyte trafficking and activation, core body temperature, plasma cytokine concentrations, bacterial clearance and survival.Results: CXCL10 was present at high concentrations in plasma and peritoneal cavity during CLP-induced septic shock. Survival was significantly improved in CXCL10 knockout (CXCL10KO) mice and mice treated with anti-CXCL10 IgG compared to controls. CXCL10KO mice and mice treated with anti-CXCL10 IgG showed attenuated hypothermia, lower concentrations of interleukin-6 (IL-6) and macrophage inhibitory protein-2 (MIP-2) in plasma and lessened natural killer (NK) cell activation compared to control mice. Compared to control mice, bacterial burden in blood and lungs was lower in CXCL10-deficient mice but not in mice treated with anti-CXCL10 IgG. Treatment of mice with anti-CXCL10 IgG plus fluids and Primaxin at 2 or 6 hours after CLP significantly improved survival compared to mice treated with non-specific IgG under the same conditions.Conclusions: CXCL10 plays a role in the pathogenesis of CLP-induced septic shock and could serve as a therapeutic target during the acute phase of septic shock.

Original languageEnglish (US)
Article numberR113
JournalCritical Care
Volume18
Issue number3
DOIs
StatePublished - Jun 2 2014

Fingerprint

Septic Shock
Immunoglobulin G
Punctures
Ligation
Knockout Mice
Chemokine CXCL10
Chemokine Receptors
Peritoneal Cavity
Lymphocyte Activation
Hypothermia
Body Temperature
Natural Killer Cells
Interleukin-6
Leukocytes
Macrophages
Cytokines
Anti-Bacterial Agents
Inflammation
Lung

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Herzig, D. S., Luan, L., Bohannon, J. K., Toliver-Kinsky, T., Guo, Y., & Sherwood, E. R. (2014). The role of CXCL10 in the pathogenesis of experimental septic shock. Critical Care, 18(3), [R113]. https://doi.org/10.1186/cc13902

The role of CXCL10 in the pathogenesis of experimental septic shock. / Herzig, Daniela S.; Luan, Liming; Bohannon, Julia K.; Toliver-Kinsky, Tracy; Guo, Yin; Sherwood, Edward R.

In: Critical Care, Vol. 18, No. 3, R113, 02.06.2014.

Research output: Contribution to journalArticle

Herzig, DS, Luan, L, Bohannon, JK, Toliver-Kinsky, T, Guo, Y & Sherwood, ER 2014, 'The role of CXCL10 in the pathogenesis of experimental septic shock', Critical Care, vol. 18, no. 3, R113. https://doi.org/10.1186/cc13902
Herzig, Daniela S. ; Luan, Liming ; Bohannon, Julia K. ; Toliver-Kinsky, Tracy ; Guo, Yin ; Sherwood, Edward R. / The role of CXCL10 in the pathogenesis of experimental septic shock. In: Critical Care. 2014 ; Vol. 18, No. 3.
@article{45114a8091904e95b91eff5940d685ef,
title = "The role of CXCL10 in the pathogenesis of experimental septic shock",
abstract = "Introduction: The chemokine CXCL10 is produced during infection and inflammation to activate the chemokine receptor CXCR3, an important regulator of lymphocyte trafficking and activation. The goal of this study was to assess the contributions of CXCL10 to the pathogenesis of experimental septic shock in mice.Methods: Septic shock was induced by cecal ligation and puncture (CLP) in mice resuscitated with lactated Ringer's solution and, in some cases, the broad spectrum antibiotic Primaxin. Studies were performed in CXCL10 knockout mice and mice treated with anti-CXCL10 immunoglobulin G (IgG). Endpoints included leukocyte trafficking and activation, core body temperature, plasma cytokine concentrations, bacterial clearance and survival.Results: CXCL10 was present at high concentrations in plasma and peritoneal cavity during CLP-induced septic shock. Survival was significantly improved in CXCL10 knockout (CXCL10KO) mice and mice treated with anti-CXCL10 IgG compared to controls. CXCL10KO mice and mice treated with anti-CXCL10 IgG showed attenuated hypothermia, lower concentrations of interleukin-6 (IL-6) and macrophage inhibitory protein-2 (MIP-2) in plasma and lessened natural killer (NK) cell activation compared to control mice. Compared to control mice, bacterial burden in blood and lungs was lower in CXCL10-deficient mice but not in mice treated with anti-CXCL10 IgG. Treatment of mice with anti-CXCL10 IgG plus fluids and Primaxin at 2 or 6 hours after CLP significantly improved survival compared to mice treated with non-specific IgG under the same conditions.Conclusions: CXCL10 plays a role in the pathogenesis of CLP-induced septic shock and could serve as a therapeutic target during the acute phase of septic shock.",
author = "Herzig, {Daniela S.} and Liming Luan and Bohannon, {Julia K.} and Tracy Toliver-Kinsky and Yin Guo and Sherwood, {Edward R.}",
year = "2014",
month = "6",
day = "2",
doi = "10.1186/cc13902",
language = "English (US)",
volume = "18",
journal = "Critical Care",
issn = "1364-8535",
publisher = "BioMed Central Ltd.",
number = "3",

}

TY - JOUR

T1 - The role of CXCL10 in the pathogenesis of experimental septic shock

AU - Herzig, Daniela S.

AU - Luan, Liming

AU - Bohannon, Julia K.

AU - Toliver-Kinsky, Tracy

AU - Guo, Yin

AU - Sherwood, Edward R.

PY - 2014/6/2

Y1 - 2014/6/2

N2 - Introduction: The chemokine CXCL10 is produced during infection and inflammation to activate the chemokine receptor CXCR3, an important regulator of lymphocyte trafficking and activation. The goal of this study was to assess the contributions of CXCL10 to the pathogenesis of experimental septic shock in mice.Methods: Septic shock was induced by cecal ligation and puncture (CLP) in mice resuscitated with lactated Ringer's solution and, in some cases, the broad spectrum antibiotic Primaxin. Studies were performed in CXCL10 knockout mice and mice treated with anti-CXCL10 immunoglobulin G (IgG). Endpoints included leukocyte trafficking and activation, core body temperature, plasma cytokine concentrations, bacterial clearance and survival.Results: CXCL10 was present at high concentrations in plasma and peritoneal cavity during CLP-induced septic shock. Survival was significantly improved in CXCL10 knockout (CXCL10KO) mice and mice treated with anti-CXCL10 IgG compared to controls. CXCL10KO mice and mice treated with anti-CXCL10 IgG showed attenuated hypothermia, lower concentrations of interleukin-6 (IL-6) and macrophage inhibitory protein-2 (MIP-2) in plasma and lessened natural killer (NK) cell activation compared to control mice. Compared to control mice, bacterial burden in blood and lungs was lower in CXCL10-deficient mice but not in mice treated with anti-CXCL10 IgG. Treatment of mice with anti-CXCL10 IgG plus fluids and Primaxin at 2 or 6 hours after CLP significantly improved survival compared to mice treated with non-specific IgG under the same conditions.Conclusions: CXCL10 plays a role in the pathogenesis of CLP-induced septic shock and could serve as a therapeutic target during the acute phase of septic shock.

AB - Introduction: The chemokine CXCL10 is produced during infection and inflammation to activate the chemokine receptor CXCR3, an important regulator of lymphocyte trafficking and activation. The goal of this study was to assess the contributions of CXCL10 to the pathogenesis of experimental septic shock in mice.Methods: Septic shock was induced by cecal ligation and puncture (CLP) in mice resuscitated with lactated Ringer's solution and, in some cases, the broad spectrum antibiotic Primaxin. Studies were performed in CXCL10 knockout mice and mice treated with anti-CXCL10 immunoglobulin G (IgG). Endpoints included leukocyte trafficking and activation, core body temperature, plasma cytokine concentrations, bacterial clearance and survival.Results: CXCL10 was present at high concentrations in plasma and peritoneal cavity during CLP-induced septic shock. Survival was significantly improved in CXCL10 knockout (CXCL10KO) mice and mice treated with anti-CXCL10 IgG compared to controls. CXCL10KO mice and mice treated with anti-CXCL10 IgG showed attenuated hypothermia, lower concentrations of interleukin-6 (IL-6) and macrophage inhibitory protein-2 (MIP-2) in plasma and lessened natural killer (NK) cell activation compared to control mice. Compared to control mice, bacterial burden in blood and lungs was lower in CXCL10-deficient mice but not in mice treated with anti-CXCL10 IgG. Treatment of mice with anti-CXCL10 IgG plus fluids and Primaxin at 2 or 6 hours after CLP significantly improved survival compared to mice treated with non-specific IgG under the same conditions.Conclusions: CXCL10 plays a role in the pathogenesis of CLP-induced septic shock and could serve as a therapeutic target during the acute phase of septic shock.

UR - http://www.scopus.com/inward/record.url?scp=84904753789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904753789&partnerID=8YFLogxK

U2 - 10.1186/cc13902

DO - 10.1186/cc13902

M3 - Article

C2 - 24890566

AN - SCOPUS:84904753789

VL - 18

JO - Critical Care

JF - Critical Care

SN - 1364-8535

IS - 3

M1 - R113

ER -